M Corachan

Publications (2)3.77 Total impact

• Article: Estimating the vaccine-preventable burden of hospitalized pneumonia among young Mozambican children.

  A Roca, B Sigaúque, Ll Quintó, L Morais, A Berenguera, M Corachan, J L Ribó, D Naniche, Q Bassat, Ch Sacoor, D Nhalungo, E Macete, A Schuchat, M Soriano-Gabarró, B Flannery, P L Alonso
  [show abstract] [hide abstract]
  ABSTRACT: Polysaccharide-protein conjugate vaccines against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae have proven efficacy against radiologically confirmed pneumonia. Measurement of pneumonia incidence provides a platform to estimate of the vaccine-preventable burden. Over 24 months, we conducted surveillance for radiologically confirmed severe pneumonia episodes among children <2 years of age admitted to a rural hospital in Manhiça, southern Mozambique. Study children were tested for HIV during the second year of surveillance. Severe pneumonia accounted for 15% of 5132 hospital admissions and 32% of in-hospital mortality among children <2 years of age. Also, 43% of chest radiographs were interpreted as radiologically confirmed pneumonia. HIV-infection was associated with 81% of fatal pneumonia episodes among children tested for HIV. The minimum incidence rate of radiologically confirmed pneumonia requiring hospitalization was 19 episodes/1000 child-years. Incidence rates among HIV-infected children were 9.3-19.0-fold higher than HIV-uninfected. Introduction of Hib and pneumococcal conjugate vaccines would have a substantial impact on pneumonia hospitalizations among African children if vaccine effects are similar to those observed in clinical trials.
  Vaccine 04/2010; 28(30):4851-7. · 3.77 Impact Factor
• Article: Estimating the vaccine-preventable burden of hospitalized pneumonia among young Mozambican children

  A. Roca, B. Sigaúque, Ll. Quintó, L. Morais, A. Berenguera, M. Corachan, J.L. Ribó, D. Naniche, Q. Bassat, Ch. Sacoor, D. Nhalungo, E. Macete, A. Schuchat, M. Soriano-Gabarró, B. Flannery, P.L. Alonso
  [show abstract] [hide abstract]
  ABSTRACT: Polysaccharide-protein conjugate vaccines against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae have proven efficacy against radiologically confirmed pneumonia. Measurement of pneumonia incidence provides a platform to estimate of the vaccine-preventable burden. Over 24 months, we conducted surveillance for radiologically confirmed severe pneumonia episodes among children <2 years of age admitted to a rural hospital in Manhiça, southern Mozambique. Study children were tested for HIV during the second year of surveillance. Severe pneumonia accounted for 15% of 5132 hospital admissions and 32% of in-hospital mortality among children <2 years of age. Also, 43% of chest radiographs were interpreted as radiologically confirmed pneumonia. HIV-infection was associated with 81% of fatal pneumonia episodes among children tested for HIV. The minimum incidence rate of radiologically confirmed pneumonia requiring hospitalization was 19 episodes/1000 child-years. Incidence rates among HIV-infected children were 9.3–19.0-fold higher than HIV-uninfected. Introduction of Hib and pneumococcal conjugate vaccines would have a substantial impact on pneumonia hospitalizations among African children if vaccine effects are similar to those observed in clinical trials.
  Vaccine.